XPeng said during its AI Day event in Guangzhou that it will launch robotaxis next year and introduce a second‑generation humanoid robot, both powered by the company’s own chips. The decision comes after the company previously said robotaxis were not a near‑term business. XPeng is now presenting itself as a company building full autonomous systems, […]XPeng said during its AI Day event in Guangzhou that it will launch robotaxis next year and introduce a second‑generation humanoid robot, both powered by the company’s own chips. The decision comes after the company previously said robotaxis were not a near‑term business. XPeng is now presenting itself as a company building full autonomous systems, […]

XPeng will launch robotaxis in 2026 using its own Turing AI chips and VLA model

XPeng said during its AI Day event in Guangzhou that it will launch robotaxis next year and introduce a second‑generation humanoid robot, both powered by the company’s own chips.

The decision comes after the company previously said robotaxis were not a near‑term business. XPeng is now presenting itself as a company building full autonomous systems, not only electric cars, according to statements made at the event.

The company said it will launch three robotaxi models, each using four Turing AI chips, which XPeng designed in‑house. The total computing performance inside the vehicle is 3,000 TOPS.

The vehicles run on the vision‑language‑action (VLA) model, which is in its second version and is built to read visual input and act without human instruction.

The robotaxi vehicles include external displays on the sun visors that show information such as speed to people outside the car. Testing will begin in Guangzhou and then expand to other Chinese cities in 2026.

Robotaxis will operate with Alibaba mapping support

XPeng is working with Alibaba, using AutoNavi and the Amaps ride‑hailing platform for routing and booking. This partnership links XPeng’s robotaxis directly into an existing navigation and transportation service rather than creating a new platform.

The move puts XPeng closer to companies pursuing large‑scale driverless fleets.

Co‑President Gu said the company has been developing some of this technology earlier than Tesla, but did not publicize it as aggressively. Gu said, “What we are pursuing from a tech and product perspective, there are some similarities with Tesla.

There are some areas that we probably started earlier than Tesla,” referencing flying cars and humanoid robotics. XPeng has already built a flying car prototype, which places it among the few automakers exploring both ground and aerial mobility products.

Gu also said Tesla has communicated commercialization plans more openly, and XPeng has not shared its work at the same scale until now.

Humanoid robots and new driver‑assist systems coming next

XPeng also introduced the second‑generation Iron humanoid robot, which is scheduled for mass production next year. The robot uses three Turing chips and a solid‑state battery.

XPeng plans to offer customization options such as different body shapes and hairstyles. CEO He Xiaopeng said the robots will not enter homes soon because the machines are still expensive, and China has low labor costs in factories.

He said the robots will first appear as tour guides, sales assistants, and office building guides, starting in XPeng’s own facilities. He said, “I don’t know how many robots we will sell in the next 10 years, but it will be more than the number of cars.”

XPeng also announced that in the first quarter of 2026, it will introduce a new driver‑assist system designed to help vehicles move through narrow roads.

XPeng said the system reduces the amount of manual input required and is well-suited for European city layouts. The company confirmed that Volkswagen will be the first outside manufacturer to use the system, and XPeng plans to offer the feature to additional automakers.

He said the new driver‑assist system required less human control than Tesla’s Full Self‑Driving (FSD) feature and completed a test route several minutes faster. Tesla has faced difficulty obtaining regulatory approval for FSD in mainland China, which has slowed deployment.

XPeng started releasing its own driver‑assist software in major Chinese cities in early 2023, and the feature has quickly become common among Chinese automakers competing in a crowded domestic EV market.

Sharpen your strategy with mentorship + daily ideas - 30 days free access to our trading program

Market Opportunity
null Logo
null Price(null)
--
----
USD
null (null) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26